Proteins and Peptides

03 Sep 2019 Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
29 Aug 2019 La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
27 Aug 2019 FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea
22 Aug 2019 Fiasp® approved in Europe for the management of diabetes in adolescents and children aged one year and above
21 Aug 2019 Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck
20 Aug 2019 Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
20 Aug 2019 Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
15 Aug 2019 Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
08 Aug 2019 89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
07 Aug 2019 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
07 Aug 2019 Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
06 Aug 2019 Inotrem Announces FDA Clearance of Investigational New Drug (IND) for the Phase IIB ASTONISH Trial in Septic Shock Patients to Demonstrate Nangibotide Efficacy
05 Aug 2019 INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer
05 Aug 2019 Antidote Therapeutics Progresses Optimization of the Nicotine-degrading Enzyme, NicA2, for Potential Use in Treating Nicotine Addiction
31 Jul 2019 Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform
29 Jul 2019 Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome
25 Jul 2019 BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
24 Jul 2019 Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
21 Jul 2019 Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
16 Jul 2019 Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
16 Jul 2019 Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
11 Jul 2019 SOTIO Initiates First-In-Human Clinical Trial with IL-15 Superagonist SO-C101
09 Jul 2019 Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin
08 Jul 2019 Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
08 Jul 2019 Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up